The percentage of the full total tissue area showing eGFP expression was calculated using Adobe Photoshop (Adobe Systems Inc. from the AAV serotype capsids to supply cardiomyocyte-specific gene appearance, but AAV-9 accompanied by AAV-8 was the most effective. AAV9-mediated Rabbit Polyclonal to ABHD12 gene appearance in the cTnT promoter was 640-collapse greater within the cardiovascular set alongside the following highest tissues (liver organ). eGFP fluorescence indicated a transduction performance of 96% using AAV-9 at a dosage of just 3.151010viral particles per mouse. Furthermore, the strength of cardiomyocyte eGFP fluorescence assessed on the cell-by-cell basis uncovered that AAV-mediated gene appearance in the heart can be modeled as a Poisson distribution; requiring an average of nearly two vector genomes per cell to attain an 85% transduction efficiency. Keywords:AAV, Cardiomyocyte-specific, Cardiac Troponin-T Promoter, Gene Therapy, Poisson distribution == Introduction == Important goals of contemporary biomedical research include elucidating the molecular basis of cardiovascular diseases and developing novel approaches for treatment and prevention. The development of efficient techniques for direct Gly-Phe-beta-naphthylamide in vivo gene transfer is important not only to expedite basic science studies in animal models, but also to realize the considerable potential for direct clinical application. However, progress to date in human gene therapy has been limited by shortcomings in the available gene delivery systems. An ideal vector system for cardiac gene therapy would deliver genes efficiently and specifically to cardiomyocytes, provide for long term gene expression, would be free of immune responses, pose minimal risk to the host, and could be administered to the heart without complicated surgical procedures. In the past, a number of methods have been employed to focus viral-mediated gene delivery to the heart: primarily by direct injection into heart muscle1,2and by complex intracoronary perfusion techniques requiring open-chest surgery to cross-clamp the aorta.3,4The use of vascular permeabilizing agents such as histamine, papaverine or substance P with cardioplegia solution and/or whole body cooling have also been employed in attempts to improve the efficiency of conventional AAV-2 vectors for transducing skeletal and cardiac myocytes in vivo.4,5Ironically, the conventional AAV serotype (AAV-2) used in the vast majority of the AAV studies performed to date suffers from a relatively low transduction rate and a prolonged lag phase (up to 6 weeks) before full expression is achieved in the heart.6,7Despite these limitations, AAV-2 vectors have often favored for clinical gene therapy protocols due to their wide range of tissue tropism and minimal vector-related immunological complications (reviewed by Wu et al.).8More recently, a number of new Gly-Phe-beta-naphthylamide AAV serotypes have been isolated, and some of these (e.g., AAV-1, AAV-6, AAV-8 and AAV-9) effectively cross the endothelial barrier to efficiently transduce a variety of organs.913The AAV-9 capsid has previously been reported to show a modest preference for cardiac tissue in vivo, both in one day old neonatal mice10,11and in adult mice.9Moreover, it has been shown that AAV9 transduction to heart, lung and tibialis anterior muscle is superior and age-independent, whereas liver and kidney are transduced poorly in one day old neonates as compared to adult mice.11 The new AAV serotypes provide for early-onset transgene expression9,14and mediate highly-efficient gene transfer to a variety of tissues in neonatal mice,10,11,13adult mice,912rats,15canines16and even non-human primates.17While desirable from the standpoint of general utility, the wide range of tissue tropism displayed by most AAV serotypes can become a liability in specific gene therapy applications where it is often important to restrict gene expression Gly-Phe-beta-naphthylamide to a particular cell type. The incorporation of gene regulatory elements conferring tissue-specific gene expression has therefore been developed as general strategy for targeting gene therapy to particular tissues of interest. As one of the 3 subunits of the troponin (troponin C, troponin T and troponin I) found in cardiac thin filaments, cardiac troponin T (cTnT) binds to tropomyosin to form the troponin-tropomyosin complex which plays an important role in regulating contractile function.18Ma et al., performed mutational analyses around the cTnT promoter region, and reported that this 375 to +43 region (relative to the cTnT transcriptional start site) is sufficient to confer cardiomyocyte-specific gene expression.19It follows that this truncated cTnT promoter might prove useful for preferentially restricting therapeutic gene expression to cardiomyocytes in the heart, both for basic science experiments and for cardiac gene therapy protocols. In the present study, we constructed AAV vectors in which the truncated cTnT promoter drives the expression of luciferase or eGFP. The resulting AAV vectors were packaged into a panel of AAV serotypes (AAV-1, 2, 6, 8 or 9). The minimal cTnT promoter.